• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300357.SZ
Share

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Stocks

CN¥ 22.7Last Updated 26.05.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.76B

CN¥ 22.7
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300357.SZ is 38 and suggests 70% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 20:33

JPMorgan finds new positive factor for US stocks growth

28.05.2026 19:22

'It's crazy': chipmaker stocks break dot-com era records. Will the rally continue?

28.05.2026 18:56

US stocks retreated from highs amid accelerating inflation and escalating war

28.05.2026 17:55

Consumer spending inflation in the US has reached a three-year high

28.05.2026 17:21

The Russian ruble has strengthened to a three-year high. What is helping it?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026